

**ASSOCIATION OF HUMAN CYTOMEGALOVIRUS WITH
HEPATITIS C VIRUS INFECTIONS AND ITS IMPACT ON
ANTIVIRAL THERAPY**

Thesis

**Submitted for partial fulfillment of MD degree in Medical
Microbiology and Immunology**

By

**Duaa Desouky Ahmed Abdelaaty
MB,BCh, MSc**

Supervisors

**Prof. Dr. Samira Abdelbaky Shoeb
Professor of Medical Microbiology and Immunology
Faculty of Medicine –Cairo University**

**Prof. Dr. Ashraf Elsayed Abd El-Hameid
Professor of Medical Microbiology and Immunology
Faculty of Medicine –Cairo University**

**Dr. Sohier Ahmed Ismael
Consultant of Hepatology and Gastroenterology National Hepatology
and Tropical Medicine Research Institute (NHTMRI)**

**Faculty of Medicine
Cairo University
2015**

محضر

اجتماع لجنة الحكم على الرسالة المقدمة من
الطبيب / دعاء دكتور احمد عبد العاليم
توطئة للحصول على درجة الماجستير / الدكتورة
في الميكروبيولوجيا الباثية والمناعة

تحت عنوان : باللغة الانجليزية : Association of Human Cytomegalovirus with Hepatitis C virus infections and its Impact on Antiviral Therapy

: باللغة العربية : التزاوج العدوي بين الفيروسات الفيروسية وفيروس التهاب الكبد الوبائي C وعلاقتها بتأثيره على الاستجابة العلاجية لمضادات الفيروسات

بناءً على موافقة الجامعة بتاريخ ١٩ / ٨ / ٢٠١٥ تم تشكيل لجنة الفحص والمناقشة للرسالة المذكورة أعلاه على النحو التالي :-

- (١) د. سحر عبد الماقى رئيس
- (٢) د. غادة عبد الرحمن /
- (٣) د. احمد شرف وهدى

بعد فحص الرسالة بواسطة كل عضو منفردا وكتابة تقارير منفردة لكل منهم لانعادت اللجنة مجتمعة في يوم الجمعة بتاريخ ١١ / ٨ / ٢٠١٥ بقسم الميكروبيولوجيا مدرج الدراسات بكلية الطب - جامعة القاهرة وذلك لمناقشة الطالب في جلسة علمية في موضوع الرسالة والنتائج التي توصل اليها وكذلك الاسس العلمية التي قام عليها البحث .

قرار اللجنة :

تم قبول الرسالة

توزيعات أعضاء اللجنة :-

المشرف المتحن

محمد


المتحن الداخلي

.....

المتحن الخارجي

د. اسراء وهدى

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ



صدق الله العظيم

(سورة طه آية 114)

Abstract

More than 170 million patients worldwide are chronically infected with HCV. CMV infection enhances HCV pathogenesis. The study was conducted to determine the response rate to treatment with pegylated interferon alpha and ribavirin in chronic HCV patients co-infected with CMV. Fifty cases were included (19 females & 13 males) referred to outpatient clinic of the national hepatology and tropical medicine research institute (NHTMRI). The study found that CMV- HCV co-infection is predominant in Egypt, and that CMV co-infection may influence HCV treatment outcome.

Key words: HCV-CMV-Interferon alpha -ribavirin .

ACKNOWLEDGEMENT

First I thank Allah for giving me the power to accomplish this work.

I would like to express my gratitude and appreciation to **Prof. Samira Abdelbaky Shoeb**, Professor of Medical Microbiology and Immunology, Faculty of Medicine – Cairo University, for giving me the honor of working under her kind supervision and her valuable remarks.

I would like to extend my deep gratitude and special appreciation to **Prof. Ashraf Elsayed Abdel- Hameid**, professor of Medical Microbiology and Immunology, Faculty of Medicine – Cairo University, for his helpful guidness and close experienced advice throw the whole work.

I would like to acknowledge **Dr. Sohier Ahmed Ismael**, Consultant of Hepatology and Gastroenterology, National Hepatology and Tropical Medicine Research Institute for her great help and advice.

I would like to convey my sincere love to my lifelong companion my husband, my daughters and my beloved mother.

Finally, to the soul of my father, the first to teach me.

SUMMARY

More than 170 million patients worldwide are chronically infected with HCV. Prevalence rates range from 0.5% in Northern European countries to 28% in some areas of Egypt. CMV infection enhances HCV pathogenesis by preventing the normal mechanisms responsible for HCV clearance, thus playing vital role in HCV persistence and pathogenicity.

This study was conducted to determine the response rate to treatment regimen of pegylated interferon alpha and Ribavirin in chronic HCV patients coinfecting with CMV, and to examine the effect of CMV coinfection on outcome of treatment with pegylated interferon alpha and Ribavirin in chronic HCV patients. The study included a total of 50 cases (19 females and 31 males) with the mean age of 41 ± 10.8 years. They were referred to the Outpatient Clinic of The National Hepatology and Tropical Medicine Research Institute (NHTMRI) to be assessed to start antiviral treatment (pegylated interferon plus ribavirin) based on laboratory and clinical decision.

To examine the role of HCMV infection in HCV response to antiviral therapy, two groups of HCV patients were classified group 1 (positive HCV PCR and negative CMV Ig G) and included 15 patients versus group 2 (positive HCV PCR and positive CMV Ig G) and included 35 patients. On comparing the effect of presence of CMV- on response to combined anti HCV treatment regimen in the 2 studied groups, the non responders were higher in group 2 (65.7 %) than in group 1 (53.3 %) but with no statistical significance.

In conclusion our study found that CMV – HCV coinfection is predominant in Egypt, and CMV co-infection may influence the HCV treatment outcome, despite it failed to have statistical significance.

LIST OF CONTENTS

List of abbreviations	i
List of figures	v
List of tables	vii
Introduction	1
Aim of work	3
HCV	4
HCV virology	4
Epidemiology of HCV infection	15
Immune response to HCV infection	21
Natural history of HCV infection	26
Diagnosis of HCV infection	32
Treatment of HCV infection	38
CMV	
Epidemiology of CMV	48
Virology of CMV	48
CMV transmission	52
Latency and reactivation	53
Immune responses to HCMV	54
CMV infection and diseases	58
CMV Treatment	60
CMV – HCV Coinfection	61
Introduction	61
Incidence of CMV in HCV patients	62

Effects of CMV/HCV coinfection	63
Effects of CMV/HCV coinfection on anti – HCV therapy	65
IL 28B polymorphism and CMV/HCV coinfection	65
Interplay between HCV and CMV molecular mechanisms	66
CMV/HCV and liver transplantation	67
Patients and methods	71
Results	84
Discussion	103
Conclusion and Recommendations	111
References	112

LIST OF ABBREVIATINS

\$	American Dollar
AASLD	The American association for the study of liver diseases
AEs	Adverse effects
AIDS	Acquired immune deficiency syndrome
AFP	Alpha fetoprotein
ALT	Alanine transaminase
APCs	Professional antigen presenting cells
ARFP	Alternate reading frame protein
AST	Aspartate transaminase
C protein	HCV core protein
Cal	Calibrator
CD	Cluster of differentiation
CDC	The centre for disease control and prevention
cDNA	Complementary DNA
CHC	Chronic hepatitis C
CLDN - 1	Claudin – 1
CMV	Cytomegalovirus
CMV - DNA	Cytomegalovirus – Deoxyribonucleia acid
CTL	Cytotoxic CD 8+ T lymphocytes
DAAs	Direct acting antivirals
DCs	Dendretic cells
DM	Diabetes mellitus
DNA	Deoxyribonucleic acid
dNTPs	Deoxy nucleotide triphosphates
E1	Membrane associated envelop glycoprotein – 1
E2	Membrane associated envelop glycoprotein – 2
EDHS	The Egyptian Demographic and Health Survey study
EASL	European Association for the Study of the Liver
EGFR	Epidermal growth factor receptor
ELISA	Enzyme Linked Immuno Sorbant Assay
EMA	European medicine association
ER	Endoplasmic reticulum
FDA	Food and drug administration
GAG	Glucoseaminoglycan
GBS	Guillian Barrè syndrome
gH	Glycoprotein H
gL	Glycoprotein L
gB	Glycoprotein B
HAV	Hepatitis A Virus
HBsAg	Hepatitis B surface antigen
HBV	Hepatitis B virus

HCC	hepatocellular carcinoma
HCMV	Human cytomegalovirus
HCMV IE genes	Human cytomegalovirus immediate early genes
HCV	hepatitis C virus
HCV - RNA	Hepatitis C virus – ribonucleic acid
HCV Ab	Hepatitis C Antibody
HIV	Human immunodeficiency virus
HLA	Human leucocytic antigen
HRP-Conjugate	Horse radish peroxidase – conjugate
IAS – USA	International antiviral society – USA
ICU	Intensive care unit
IDSA	Infectious disease society of America
IE1	Immediate early protein 1
IE2	Immediate early protein 2
IFN γ	Interferon gama
IFNs	Interferons
Ig G	Immunoglobulin G
IgM	Immunoglobulin M
IL - 2	Interleukin 2
IL - 6	Interleukin 6
IL - 8	Interleukin 8
IL - 10	Interleukin 10
IL - 12	Interleukin 12
IL - 15	Interleukin 15
IL - 21	Interleukin 21
IL28B gene	Interleukin 28 B gene
IR	Insulin resistance
IRES	Internal ribosome entry site
ISGF3	Interferon stimulated gene factor 3
ISGs	Interferon stimulated genes
ISRE	Interferon stimulated response element
IU/ml	International unit per milliliter
IV	Intravenous
JAK - STAT	Janus kinase – signal transducer and activator of transcription
kPa	Kilopascal
LDL	Low density lipoprotein
LDL – R	Low density lipoprotein receptor
LDs	Lipid droplets
mDCs	Myeloid dendretic cells
MHC	Major histocompatibility complex
miR-122	Micro RNA - 122
ml	Milli liter

Mn₂	Manganese
NAFLD	No n alcoholic fatty liver disease
NF-κB	Nuclear factor κ B
NHTMRI	National hepatology and tropical medicine research institute
NK	Natural killer cell
Nm	Nanometer
NR	Non responders
NS	Non structural protein
NS2	Non structural protein 2
NS3	Non structural protein 3
NS3/4A PIs	Non structural protein 3/4 A protease inhibitors
NS4A	Non structural proteins 4 A
NS4B	Non structural proteins 4 B
NS5A	Non structural proteins 5 A
NS5B	Non structural proteins 5 B
NTR	Non translated region
Nt	Nucleotide
OAS1	oligoadenylate synthetase 1
OCLN	Occludin
OD	Optical density
OLT	Orthotropic liver transplantation
ORF	Open reading frame
P48	Protein 48
PAMPs	Pathogen associated molecular patterns
PAT	Parental anti shistosomal therapy
PCR	Polymerase chain reaction
pDCs	Plasmacytoid dendretic cells
PDGFR α	Platelet derived growth factor receptor alpha
PegIFN	Pegylated interferon
PIs	Protease inhibitors
PKR	Protein kinase R
QS	Quantitation standard
RBCs	Red blood cells
RBV	Ribavirin
RdRNAP	RNA dependant-RNA polymerase
RIBA	Recombinant immunoblot assay
RIG –I	Retinoic acid – inducible gene I
RNA	Ribonucleic acid
RR	Relapsed responders
S/CO	Sample – cut off
SNPs	Single nucleotide polymorphism
SOT	Solid organ transplantation

SR – B1	Scavenger receptor B type 1
SVR	Sustained virological response
TGF -β	Transformation growth factor beta
Th	T helper cells
Th 1	T helper cell type 1
Th 17	T helper cell 17
Th 2	T helper cell type 2
TIMP- 1	Tissue inhibitors of metalloproteinases - 1
TIMPs	Tissue inhibitors of metalloproteinases
TLR -3	Toll like receptor 3
TMA	Transcription mediated amplification
TNF α	Tumor necrosis factor alpha
Treg	T regulatory cells
Tδ	T helper delta subtype
UL	Unique long segment
UL54	Unique long segment 54 gene region
US	Unique short segment
USA	United states of America
UTR	Untranslated reigon
VLDL	Very low density lipoprotein
WHO	World health organization
μl	Micro liter
bDNA	Branched DNA
EIA	Enzyme immunoassay

LIST OF FIGURES

Figure	Subject	Page
Fig 1	HCV particle structure	5
Fig 2	HCV genome	5
Fig 3	HCV viral cycle	11
Fig 4	HCV receptors for cell entry	12
Fig 5	Global prevalence of CHC infection	15
Fig 6	Sources of acute hepatitis C infection by geographic region	17
Fig 7	HCV prevalence among adults and genotype distribution	20
Fig 8	Natural killer (NK) cells in acute HCV infection	22
Fig 9	Function of dendritic cells in viral immune response	24
Fig 10	Natural history of HCV infection	26
Fig 11	Classification of chronic liver disease based on histological, clinical, hemodynamic, and biological parameters	29
Fig 12	HCMV various components	49
Fig 13	Life cycle of HCMV in a human cell	50
Fig 14	Immune control of HCMV by innate and adaptive immunity	54
Fig 15	Calibration curve	78
Fig 16	Quantitation standard growth curves from specimens from a viral dilution series that Spans a 5-log 10 Range	83
Fig 17	Correlation between gender and anti CMV-IgG status in both groups	86
Fig 18a and 18b	The mean value of anti CMV- IgG levels in group 2 patients' pre and post HCV treatment	87
Fig 19	Relation between gender and baseline anti CMV-IgG levels in group 2	88
Fig 20	Relation between gender and post treatment anti CMV-IgG in group 2	89
Fig 21	Correlation between patients' age and anti CMV- IgG levels before and after treatment in group 2	90
Fig 22	Relation between CMV- presence and response to combined anti HCV treatment in the 2 studied groups	91
Fig 23	Comparison of age of non responders in both groups	92
Fig 24	Correlation between baseline anti CMV- IgG levels and baseline HCV- PCR viral load levels in group 2	93
Fig 25	Correlation between age and baseline PCR in the studied groups	95

Fig 26	Relation between patients' age and response to HCV treatment	96
Fig 27	Relation between gender and baseline HCV-RNA viral load PCR in the studied population	97
Fig 28	Relation between gender and post treatment HCV - PCR in non responders	98
Fig 29 a and b	Correlation between HCV - PCR pre and post antiviral treatment in the non-responders cases in both groups	100
Fig 30 a and b	Comparison between HCV - PCR pre and post anti viral treatment in the non responders in group 2	101
Fig 31	Comparison between HCV - PCR pre and post anti viral treatment in the non responders in group 1	102

LIST OF TABLES

Table	Subject	Page
Table 1	Interpretation of test results for HCV infection	37
Table 2	Therapies for treatment –Naïve patients	47
Table 3	Distribution of studied population according to their age	85
Table 4	Distribution of studied population according to their gender	85
Table 5	correlation between gender and anti CMV-IgG status in both groups	86
Table 6	The mean value of anti CMV- IgG levels in group 2 patients' pre and post HCV treatment	87
Table 7	Relation between gender and baseline anti CMV-IgG levels in group 2	88
Table 8	Relation between gender and post treatment anti CMV- IgG in group 2	89
Table 9	Correlation between patients' age and anti CMV- IgG levels before and after treatment in group 2	90
Table 10	Relation between CMV- presence and response to combined anti HCV treatment in the 2 studied groups	91
Table 11	Comparison of age and CMV presence of non responders in both groups	92
Table 12	Correlation between baseline anti CMV- IgG levels and baseline HCV- PCR viral load levels in group 2	93
Table 13	Correlation between post treatment anti CMV- IgG levels and Post treatment HCV- PCR viral load levels in non responders of group 2	94
Table 14	Correlation between age and baseline PCR in the studied groups	95
Table 15	Relation between patients' age and response to HCV treatment	96
Table 16	Relation between gender and baseline HCV-RNA viral load PCR in the studied population	97
Table 17	Relation between gender and post treatment HCV - PCR in non responders of both groups	98
Table 18	Relation between gender and post treatment PCR in the non responders in group 1	99
Table 19	Relation between gender and post treatment PCR in the non responders in group 2	99